创新药概念再度活跃，华森制药4连板，舒泰神9个交易日大涨超140%

Group 1 - The innovative drug concept has become active again, with companies like Ruizhi Pharmaceutical reaching a 20% limit up, and others like Kexing Pharmaceutical and Shutaishen rising over 15% [1] - Huason Pharmaceutical has achieved a continuous limit up for four trading days, receiving approval from the Health Sciences Authority of Singapore for its traditional Chinese medicine product, Tongxie Ning granules, which is the first natural plant drug for treating IBS-D globally [1][2] - Tongxie Ning granules are derived from a classic formula and are noted for their efficacy in treating IBS through multiple pathways and targets, with high safety and significant effectiveness [1] Group 2 - Huason Pharmaceutical's recent approval marks the fourth product to achieve overseas registration, enhancing the company's international market recognition [2] - Although the product has not yet been commercialized overseas, successful commercialization could positively impact the company's performance, though it faces uncertainties from market policies, exchange rate fluctuations, and competition [2] - Shutaishen has seen a cumulative increase of over 140% in the last nine trading days, with attention on its subsidiary's application for priority review of the injectable STSP-0601, which is currently in the public notice period [2]